Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

November 9, 2023

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024

Sufficient Cash to Fund Planned Operations into First Half of 2025

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.

“The NX-13 Phase 2 clinical program (NEXUS) remains our top priority, and we are pleased with our execution and progress during the third quarter,” said Gregory Oakes, President and CEO of Landos. “We believe NX-13 can deliver on the potential of immunometabolism and its role in breaking the inflammatory cycle for the millions of patients suffering from moderate-to-severe ulcerative colitis.”

Third Quarter 2023 Clinical Development Highlights

NX-13 is a novel, gut-selective NLRX1 agonist in development as a once-daily, oral treatment for ulcerative colitis (UC).

- NEXUS Phase 2 proof-of-concept clinical trial:
  - The NEXUS trial of NX-13 remains on track as the Company continues to recruit, screen and randomize patients for the trial.
  - 20 sites in the United States and Europe have been activated.
  - NEXUS is a randomized, statistically powered, multicenter, double-blind, placebo-controlled, multiple dose, 12-week induction study evaluating 80 patients with moderate-to-severe UC with a long-term extension (LTE) period out to one year. All subjects will be randomized to receive either a 250 mg or 750 mg immediate release dose of NX-13 or placebo. The primary objective of the trial is to evaluate the clinical efficacy, safety and pharmacokinetics of oral NX-13 vs. placebo (NCT05785715 ClinicalTrials.gov).
  - NEXUS top-line results are expected to be reported in the fourth quarter of 2024.
- In September 2023, the Company announced a strategic research collaboration with the Inflammatory Bowel Disease Team at KU Leuven and University Hospitals Leuven, a leading European research university and hospital network known for its innovation in Leuven, Belgium. The goal of this collaboration is to further characterize the effects of NX-13 on epithelial cells using UC patient-derived organoid models that mimic in vivo conditions while allowing for controlled in vitro studies. The results are expected to provide additional insights regarding the impact of NX-13 on gene expression, gene regulation and cytokine responses. Results from this research collaboration are expected to be presented at appropriate medical conferences in 2024.
- In October 2023, the Company presented additional findings from its Phase 1b study of NX-13 for the treatment of UC, including detailed results on the rapid symptomatic relief and improvement in multiple biomarkers observed in the study.
  - Presented two oral presentations and one poster at the United European Gastroenterology Week (UEGW) 2023.
  - Presented three posters at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting.

Third Quarter 2023 Financial Highlights

- As of September 30, 2023, the Company had cash, cash equivalents and marketable securities of $42.5 million, which it believes will be sufficient to fund operating expenses and capital requirements into the first half of 2025.
- Research and development expenses were $3.1 million for the third quarter of 2023, compared to $4.9 million for the third quarter of 2022. The decrease was primarily attributable to the wind down of omilancor and LABP-104 clinical trials and a reduction in NX-13 Phase 1b clinical trial costs, partially offset by initiation of the NEXUS trial. Additionally, there were increases in compensation costs, partially offset by a decrease in consulting costs.
- General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.0 million for the third quarter of 2022. The decrease was primarily attributable to decreased costs in consulting and Directors & Officers (D&O) insurance.

About Landos Biopharma

Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with

autoimmune diseases. Our mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm.

We have a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space.

We are currently focused on advancing the clinical development of NX-13 in UC. We initiated the NEXUS Phase 2 proof-of-concept trial in the second quarter of 2023 and expect to report topline results by the fourth quarter of 2024.

For more information, please visit www.landosbiopharma.com.

Cautionary Note on Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects for Landos Biopharma, Inc. (the "Company"), including statements about the Company's strategy, clinical development and regulatory plans for its product candidates and other statements containing the words "anticipate", "plan", "expect", "may", "will", "could", "believe", "look forward", "potential", the negatives thereof, variations thereon and similar expressions, or any discussions of strategy constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of current and future clinical trials, including the ongoing Phase 2 trial of NX-13, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates, our anticipated cash runway and other similar risks. Risks regarding the Company's business are described in detail in its Securities and Exchange Commission ("SEC") filings, including in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Contacts

Rebecca Mosig, Vice President, Corporate Development
Landos Biopharma
jr@landosbiopharma.com

John Mullaly
LifeSci Advisors, LLC
jmullaly@lifesciadvisors.com

Landos Biopharma, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Operating expenses:				
Research and development	$ 3,063	$ 4,862	$ 8,852	$ 22,266
General and administrative	2,136	2,967	7,265	11,782
Total operating expenses	5,199	7,829	16,117	34,048
Loss from operations	(5,199)	(7,829)	(16,117)	(34,048)
Other (expense) income, net	(661)	(67)	301	4
Net loss	$ (5,860)	$ (7,896)	$ (15,816)	$ (34,044)
Net loss per share, basic and diluted	$ (0.94)	$ (1.96)	$ (2.51)	$ (8.46)
Weighted-average shares used to compute net loss per share, basic and diluted	6,207,638	4,025,489	6,298,846	4,025,489

Landos Biopharma, Inc. Condensed Consolidated Balance Sheets (in thousands)

	September 30, 2023	December 31, 2022
	(Unaudited)	
Assets		
Current assets:		
Cash and cash equivalents	$ 42,408	$ 36,640
Marketable securities, available-for-sale	62	7,762
Restricted cash	50	—

Prepaid expenses and other current assets	710	851
Total current assets	43,230	45,253
Total assets	$ 43,230	$ 45,253
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	$ 1,135	$ 3,435
Accrued liabilities	4,431	2,687
Total current liabilities	5,566	6,122
Total liabilities	5,566	6,122
Commitments and contingencies		
Stockholders’ equity:		
Common stock	31	40
Additional paid-in capital	186,877	172,575
Accumulated other comprehensive loss	(1)	(57)
Accumulated deficit	(149,243)	(133,427)
Total stockholders’ equity	37,664	39,131
Total liabilities and stockholders’ equity	$ 43,230	$ 45,253